Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • Galectin Therapeutics, Inc. (GALT) Names New Executive Director Of Regulatory Affairs And Quality Assurance 0 comments
    Jan 15, 2013 2:14 PM | about stocks: GALT

    Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer. The therapies are based on the company's unique understanding of galectin proteins, which are key mediators of biological and pathologic functions.

    The company reported today that it had hired Rex Horton as Executive Director of Regulatory Affairs and Quality Assurance. Mr. Horton is an experienced industry professional with 20 years of management and leadership experience in global regulatory matters including drugs, biologics, and vaccines. He has expertise spanning preclinical development through new drug approvals in a number of diverse therapeutic areas.

    Horton most recently was Director of Regulatory Affairs at Chelsea Therapeutics where he successfully led the company through its first NDA filing and favorable FDA advisory committee meeting. In prior leadership roles at Solvay Pharmaceuticals and Abbott Laboratories, he led approval efforts for key products including Androgel Stickpack, Creon Capsules, and Luvox CR Capsules.

    Galectin Therapeutics' appointment of Mr. Horton comes at a crucial time for the company. It is at a pivotal stage in its development of carbohydrate compounds for the treatment of cancer and liver fibrosis. The company is poised to submit an IND for GR-MD-02 for treatment of non-alcoholic steatohepatitius (NYSEARCA:NASH) with fibrosis and expects to begin a Phase 1 clinical trial in early in 2013.

    For additional information about Galectin Therapeutics and its novel treatments pipeline, please visit www.galectintherapeutics.com

    Sign up for "The Mission Report" at www.MissionIR.com

    Stocks: GALT
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.